본문 바로가기
KERD
논문KCI 등재

Contemporary Pharmacotherapeutics and the Management of Aggressive Behavior in an Adolescent Animal Model of Maladaptive Aggression

Clare Einberger|Amanda Puckett|Lesley Ricci|Richard Melloni Jr.
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2020.05|Clinical Psychopharmacology and Neuroscience|제18권 제2호|pp. 188-202|DOI 10.9758/cpn.2020.18.2.188

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

AdolescentAggressionPharmacotherapyAntipsychotic agentsAnticonvulsants

초록

Objective: Antipsychotic and anticonvulsant medications are increasingly being used as pharmacotherapeutic treatments for maladaptive aggression in youth, yet no information is available regarding whether these drugs exhibit aggressionspecific suppression in preclinical studies employing adolescent animal models of maladaptive aggression. This study examined whether the commonly used antipsychotics medications haloperidol and risperidone and the anticonvulsant medication valproate exert selective aggression-suppressing effects using a validated adolescent animal model of maladaptive aggression. Methods: Twenty-seven-day old Syrian hamsters (Mesocricetus auratus) were administered testosterone for 30 consecutive days during the first 4 weeks of adolescent development. The following day (during late adolescence), experimental animals received a single dose of haloperidol (0.00, 0.025, 0.50, 1.0 mg/kg), risperidone (0.00, 0.01, 0.03, 1.0 mg/kg), or valproate (0.00, 1.0, 5.0, 10.0 mg/kg) and tested for offensive aggression using the Resident/Intruder Paradigm. As a baseline, non-aggressive behavioral control, a separate set of pubertal hamsters was treated with sesame oil vehicle during the first 4 weeks of adolescence and then tested for aggression during late adolescence in parallel with the haloperidol, risperidone or valproate-treated experimental animals. Results: Risperidone and valproate selectively reduced the highly impulsive and intense maladaptive aggressive phenotype in a dose-dependent fashion. While haloperidol marginally reduced aggressive responding, its effects were non-specific as the decrease in aggression was concurrent with reductions in a several ancillary (non-aggressive) behaviors. Conclusion: These studies provide pre-clinical evidence that the contemporary pharmacotherapeutics risperidone and valproate exert specific aggression-suppressing effects in an adolescent animal model of maladaptive aggression.

Abstract

Objective: Antipsychotic and anticonvulsant medications are increasingly being used as pharmacotherapeutic treatments for maladaptive aggression in youth, yet no information is available regarding whether these drugs exhibit aggressionspecific suppression in preclinical studies employing adolescent animal models of maladaptive aggression. This study examined whether the commonly used antipsychotics medications haloperidol and risperidone and the anticonvulsant medication valproate exert selective aggression-suppressing effects using a validated adolescent animal model of maladaptive aggression. Methods: Twenty-seven-day old Syrian hamsters (Mesocricetus auratus) were administered testosterone for 30 consecutive days during the first 4 weeks of adolescent development. The following day (during late adolescence), experimental animals received a single dose of haloperidol (0.00, 0.025, 0.50, 1.0 mg/kg), risperidone (0.00, 0.01, 0.03, 1.0 mg/kg), or valproate (0.00, 1.0, 5.0, 10.0 mg/kg) and tested for offensive aggression using the Resident/Intruder Paradigm. As a baseline, non-aggressive behavioral control, a separate set of pubertal hamsters was treated with sesame oil vehicle during the first 4 weeks of adolescence and then tested for aggression during late adolescence in parallel with the haloperidol, risperidone or valproate-treated experimental animals. Results: Risperidone and valproate selectively reduced the highly impulsive and intense maladaptive aggressive phenotype in a dose-dependent fashion. While haloperidol marginally reduced aggressive responding, its effects were non-specific as the decrease in aggression was concurrent with reductions in a several ancillary (non-aggressive) behaviors. Conclusion: These studies provide pre-clinical evidence that the contemporary pharmacotherapeutics risperidone and valproate exert specific aggression-suppressing effects in an adolescent animal model of maladaptive aggression.

참고문헌 (90)

  1. Connor DF, "Aggression and antisocial behavior in children and adolescents : research and treatment" (2002), Guilford Press
  2. Kessler RC, "The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey replication", Arch Gen Psychiatry, 63, pp.669~678 (2006)
  3. Vitaro F, "Reactive and proactive aggression differentially predict later conduct problems", J Child Psychol Psychiatry, 39, pp.377~385 (1998)
  4. Haller J, "Normal and abnormal aggression : human disorders and novel laboratory models", Neurosci Biobehav Rev, 30, pp.292~303 (2006)
  5. Kanne SM, "Aggression in children and adolescents with ASD : prevalence and risk factors", J Autism Dev Disord, 41, pp.926~937 (2011)
  6. Dyer KF, "Anger, aggression, and self-harm in PTSD and complex PTSD", J Clin Psychol, 65, pp.1099~1114 (2009)
  7. Harris AW, "Clinical and cognitive associations with aggression in the first episode of psychosis", Aust N Z J Psychiatry, 44, pp.85~93 (2010)
  8. Doerfler LA, "Aggression, ADHD symptoms, and dysphoria in children and adolescents diagnosed with bipolar disorder and ADHD", J Affect Disord, 131, pp.312~319 (2011)
  9. Ballester J, "Is bipolar disorder specifically associated with aggression", Bipolar Disord, 14, pp.283~290 (2012)
  10. Pingault JB, "Childhood hyperactivity, physical aggression and criminality : a 19-year prospective population-based study", PLoS One, 8, pp.e62594~ (2013)
  11. Connor DF, "Prevalence and patterns of psychotropic and anticonvulsant medication use in children and adolescents referred to residential treatment", J Child Adolesc Psychopharmacol, 8, pp.27~38 (1998)
  12. Connor DF, "Combined pharmacotherapy in children and adolescents in a residential treatment center", J Am Acad Child Adolesc Psychiatry, 36, pp.248~254 (1997)
  13. Knapp P, "Treatment of maladaptive aggression in youth: CERT guidelines I. Engagement, assessment, and management", Pediatrics, 129, pp.e1562~e1576 (2012)
  14. Schur SB, "Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review", J Am Acad Child Adolesc Psychiatry, 42, pp.132~144 (2003)
  15. Findling RL, "Use of antipsychotics in children and adolescents", J Clin Psychiatry, 66(Suppl 7), pp.29~40 (2005)
  16. Saxena K, "Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder", J Child Adolesc Psychopharmacol, 16, pp.252~259 (2006)
  17. Alexander GC, "Increasing off-label use of antipsychotic medications in the United States, 1995-2008", Pharmacoepidemiol Drug Saf, 20, pp.177~184 (2011)
  18. Comer JS, "National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007", J Am Acad Child Adolesc Psychiatry, 49, pp.1001~1010 (2010)
  19. Olfson M, "National trends in the outpatient treatment of children and adolescents with antipsychotic drugs", Arch Gen Psychiatry, 63, pp.679~685 (2006)
  20. Campbell M, "A comparison in hospitalized aggressive children with conduct disorder", Arch Gen Psychiatry, 41, pp.650~656 (1984)
  21. Pringsheim T, "The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine", Can J Psychiatry, 60, pp.42~51 (2015)
  22. Gorman DA, "Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder", Can J Psychiatry, 60, pp.62~76 (2015)
  23. van Schalkwyk GI, "Antipsychotics for aggression in adults : a meta-analysis", Prog Neuropsychopharmacol Biol Psychiatry, 81, pp.452~458 (2018)
  24. Arana GW, "An overview of side effects caused by typical antipsychotics", J Clin Psychiatry, 61(Suppl 8), pp.5~11 (2000)
  25. Harrison-Woolrych M, "Safety and usage of atypical antipsychotic medicines in children : a nationwide prospective cohort study", Drug Saf, 30, pp.569~579 (2007)
  26. Aman MG, "Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence", Am J Psychiatry, 159, pp.1337~1346 (2002)
  27. Van Bellinghen M, "Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning : a double-blind, placebo-controlled pilot trial", J Child Adolesc Psychopharmacol, 11, pp.5~13 (2001)
  28. Findling RL, "A double-blind pilot study of risperidone in the treatment of conduct disorder", J Am Acad Child Adolesc Psychiatry, 39, pp.509~516 (2000)
  29. McCracken JT, "Risperidone in children with autism and serious behavioral problems", N Engl J Med, 347, pp.314~321 (2002)
  30. Kavoussi RJ, "Divalproex sodium for impulsive aggressive behavior in patients with personality disorder", J Clin Psychiatry, 59, pp.676~680 (1998)
  31. Barzman DH, "The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s)", J Child Adolesc Psychopharmacol, 16, pp.665~670 (2006)
  32. Steiner H, "Divalproex sodium for the treatment of conduct disorder : a randomized controlled clinical trial", J Clin Psychiatry, 64, pp.1183~1191 (2003)
  33. Vitiello B, "Subtypes of aggression and their relevance to child psychiatry", J Am Acad Child Adolesc Psychiatry, 36, pp.307~315 (1997)
  34. Bambauer KZ, "Characteristics of aggression in clinically referred children", CNS Spectr, 10, pp.709~718 (2005)
  35. Blanchard DC, "What can animal aggression research tell us about human aggression?", Horm Behav, 44, pp.171~177 (2003)
  36. "Psychopharmacol Bull", 1977, 14~15
  37. Eichelman B, "Aggressive behavior: from laboratory to clinic. Quo vadit?", Arch Gen Psychiatry, 49, pp.488~492 (1992)
  38. Blair RJ, "The roles of orbital frontal cortex in the modulation of antisocial behavior", Brain Cogn, 55, pp.198~208 (2004)
  39. Rodríguez-Arias M, "Effects of risperidone and SCH 23390 on isolation-induced aggression in male mice", Eur Neuropsychopharmacol, 8, pp.95~103 (1998)
  40. Skrebuhhova-Malmros T, "The serotonin 5-HT(2A)receptor subtype does not mediate apomorphine-induced aggressive behaviour in male Wistar rats", Pharmacol Biochem Behav, 67, pp.339~343 (2000)
  41. Moechars D, "Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs", Neuroreport, 9, pp.3561~3564 (1998)
  42. Ricci LA, "Risperidone exerts potent anti-aggressive effects in a developmentally immature animal model of escalated aggression", Biol Psychiatry, 62, pp.218~225 (2007)
  43. Schwartzer JJ, "Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression", Psychopharmacology(Berl), 203, pp.653~663 (2009)
  44. Grimes JM, "Plasticity in anterior hypothalamic vasopressin correlates with aggression during anabolic-androgenic steroid withdrawal in hamsters", Behav Neurosci, 120, pp.115~124 (2006)
  45. Harrison RJ, "Chronic anabolic-androgenic steroid treatment during adolescence increases anterior hypothalamic vasopressin and aggression in intact hamsters", Psychoneuroendocrinology, 25, pp.317~338 (2000)
  46. Melloni RH Jr, "Adolescent exposure to anabolic", androgenic steroids and the neurobiology of offensive aggression : a hypothalamic neural model based on findings in pubertal Syrian hamsters, 2010, pp.58, 177~191
  47. Morrison TR, "Anabolic steroids alter the physiological activity of aggression circuits in the lateral anterior hypothalamus", Neuroscience, 315, pp.1~17 (2016)
  48. Miczek KA, "Neurosteroids, GABAA receptors, and escalated aggressive behavior", Horm Behav, 44, pp.242~257 (2003)
  49. Ferris CF, "Vasopressin", serotonin interactions in the anterior hypothalamus control aggressive behavior in golden hamsters, 1997, pp.17, 4331~4340
  50. Teixeira EH, "Atypical antipsychotics in the treatment of pathological aggression in children and adolescents : literature review and clinical recommendations", Trends Psychiatry Psychother, 35, pp.151~159 (2013)
  51. Miller LL, "Physical and behavioral aspects of sexual maturation in male golden hamsters", J Comp Physiol Psychol, 91, pp.245~259 (1977)
  52. Whitsett JM, "The development of aggressive and marking behavior in intact and castrated male hamsters", Horm Behav, 6, pp.47~57 (1975)
  53. Ricci LA, "Serotonin type 3 receptors modulate the aggression-stimulating effects of adolescent cocaine exposure in Syrian hamsters(Mesocricetus auratus)", Behav Neurosci, 118, pp.1097~1110 (2004)
  54. Ricci LA, "Serotonin type 3 receptors stimulate offensive aggression in Syrian hamsters", Behav Brain Res, 156, pp.19~29 (2005)
  55. West GB, "The origin of allometric scaling laws in biology from genomes to ecosystems : towards a quantitative unifying theory of biological structure and organization", J Exp Biol, 208, pp.1575~1592 (2005)
  56. Sharma V, "To scale or not to scale : the principles of dose extrapolation", Br J Pharmacol, 157, pp.907~921 (2009)
  57. Floody OR, "Aggressive behavior in female hamsters : the hormonal basis for fluctuations in female aggressiveness correlated with estrous state", J Comp Physiol Psychol, 91, pp.443~464 (1977)
  58. Lerwill CJ, "The agonistic behaviour of the golden hamster Mesocricetus auratus(waterhouse)", Animal Behav, 19, pp.714~721 (1971)
  59. Grimes JM, "Glutamic acid decarboxylase(GAD65)immunoreactivity in brains of aggressive, adolescent anabolic steroid-treated hamsters", Horm Behav, 44, pp.271~280 (2003)
  60. Reyes M, "Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study", Eur Child Adolesc Psychiatry, 15, pp.97~104 (2006)
  61. Melloni RH Jr, "Neuropathology of drug addictions and substance misuse", pp.945~957 (2016), Academic Press
  62. Schotte A, "Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography", Brain Res, 631, pp.191~202 (1993)
  63. Arregui A, "Effects of two selective dopaminergic antagonists on ethologically-assessed encounters in male mice", Gen Pharmacol, 24, pp.353~356 (1993)
  64. Navarro JF, "Acute and subchronic effects of tiapride on isolation-induced aggression in male mice", Pharmacol Biochem Behav, 58, pp.255~259 (1997)
  65. Nikulina EM, "Role of dopamine receptors in the regulation of aggression in mice; relationship to genotype", Neurosci Behav Physiol, 22, pp.364~369 (1992)
  66. Vukhac KL, "Dopamine D2L receptor-and age-related reduction in offensive aggression", Neuroreport, 12, pp.1035~1038 (2001)
  67. Wommack JC, "Repeated exposure to social stress alters the development of agonistic behavior in male golden hamsters", Horm Behav, 43, pp.229~236 (2003)
  68. Wommack JC, "Repeated social stress and the development of agonistic behavior : individual differences in coping responses in male golden hamsters", Physiol Behav, 80, pp.303~308 (2003)
  69. Delville Y, "Stress and the development of agonistic behavior in golden hamsters", Horm Behav, 44, pp.263~270 (2003)
  70. Leysen JE, "Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity", J Clin Psychiatry, 55(Suppl), pp.5~12 (1994)
  71. McKernan RM, "Which GABAA-receptor subtypes really occur in the brain?", Trends Neurosci, 19, pp.139~143 (1996)
  72. Löscher W, "Valproate : a reappraisal of its pharmacodynamic properties and mechanisms of action", Prog Neurobiol, 58, pp.31~59 (1999)
  73. Brown GL, "Aggression, suicide, and serotonin : relationships to CSF amine metabolites", Am J Psychiatry, 139, pp.741~746 (1982)
  74. Brown GL, "Aggression in humans correlates with cerebrospinal fluid amine metabolites", Psychiatry Res, 1, pp.131~139 (1979)
  75. Higley JD, "Cerebrospinal fluid monoamine and adrenal correlates of aggression in free-ranging rhesus monkeys", Arch Gen Psychiatry, 49, pp.436~441 (1992)
  76. Kyes RC, "Aggression and brain serotonergic responsivity : response to slides in male macaques", Physiol Behav, 57, pp.205~208 (1995)
  77. Mehlman PT, "Low CSF 5-HIAA concentrations and severe aggression and impaired impulse control in nonhuman primates", Am J Psychiatry, 151, pp.1485~1491 (1994)
  78. Miczek KA, "Para-chlorophenylalanine, serotonin, and killing behavior", Pharmacol Biochem Behav, 3, pp.355~361 (1975)
  79. Miczek KA, "Brain 5-HT and inhibition of aggressive behavior in animals : 5-HIAA and receptor subtypes", Psychopharmacol Bull, 25, pp.399~403 (1989)
  80. Vergnes M, "Selective increase of offensive behavior in the rat following intrahypothalamic 5, 7-DHT-induced serotonin depletion", Behav Brain Res, 29, pp.85~91 (1988)
  81. Sakaue M, "Modulation by 5-hT2A receptors of aggressive behavior in isolated mice", Jpn J Pharmacol, 89, pp.89~92 (2002)
  82. Sánchez C, "The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice", Psychopharmacology(Berl), 110, pp.53~59 (1993)
  83. Shih JC, "Ketanserin and tetrabenazine abolish aggression in mice lacking monoamine oxidase A", Brain Res, 835, pp.104~112 (1999)
  84. Rodgers RJ, "GABAergic influences on defensive fighting in rats", Pharmacol Biochem Behav, 17, pp.451~456 (1982)
  85. Shaikh MB, "GABA-mediated regulation of feline aggression elicited from midbrain periaqueductal gray", Brain Res, 507, pp.51~56 (1990)
  86. Schwartzer JJ, "Adolescent anabolic-androgenic steroid exposure alters lateral anterior hypothalamic serotonin-2A receptors in aggressive male hamsters", Behav Brain Res, 199, pp.257~262 (2009)
  87. Schwartzer JJ, "Interactions between the dopaminergic and GABAergic neural systems in the lateral anterior hypothalamus of aggressive AAS-treated hamsters", Behav Brain Res, 203, pp.15~22 (2009)
  88. Coccaro EF, "Fluoxetine and impulsive aggressive behavior in personality-disordered subjects", Arch Gen Psychiatry, 54, pp.1081~1088 (1997)
  89. Khanzode LA, "Efficacy profiles of psychopharmacology : divalproex sodium in conduct disorder", Child Psychiatry Hum Dev, 37, pp.55~64 (2006)
  90. Steiner H, "Psychopharmacologic strategies for the treatment of aggression in juveniles", CNS Spectr, 8, pp.298~308 (2003)

관련 논문AI추천

A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct DisorderBörte Gürbüz Özgür, Hatice Aksu, Sevcan Karakoç Demirkaya대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2017 · 제15권 제4호Clozapine in the Treatment of Aggression in Conduct Disorder in Children and Adolescents: A Randomized, Double-blind, Controlled TrialAntonio Costilla Esquivel, Dionicio Ángel Galarza Delgado, Lilia Marytza Leal Isida, Lourdes Garza Ocañas, Manuel E. de la O Cavazos, Myrthala Juárez-Treviño, Rosalinda Sepúlveda Sepúlveda대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2019 · 제17권 제1호Long-term Effects of Aripiprazole Treatment during Adolescence on Cognitive Function and Dopamine D2 Receptor Expression in Neurodevelopmentally Normal Rats박수빈, Chul-Eung Kim, Hae Ri Park, Hyung Jun Choi, Seunghyong Ryu, Soo Jung Im대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2019 · 제17권 제3호Plasma Risperidone-related Measures in Children and Adolescents with Oppositional Defiant/Conduct DisordersAndreas Conca, Daria Piacentino, Ekkehard Haen, Georgios D. Kotzalidis, Georgios Schoretsanitis, Giancarlo Giupponi, Michael Grözinger, Michael Paulzen, Simone Cappelletti대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2020 · 제18권 제1호Efficacy and Safety Profile of Risperidone Long-acting Injection in Adolescents in a Real-life SettingEyüp Sabri Ercan, Mustafa Küçükköse, Sevim Berrin Inci, Ulku Akyol Ardic대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2018 · 제16권 제1호Valproic Acid Exposure during Early Postnatal Gliogenesis Leads to Autistic-like Behaviors in Rats이재원, 이희제, Cheryl Dreyfus, Emanuel DiCicco-Bloom, Tamanna Jahan Mony대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2016 · 제14권 제4호

이 간행물의 다른 논문 (17건)

The Role of the SLC Transporters Protein in the Neurodegenerative DisordersAsli Aykaç, Ahmet Özer Şehirlipp. 174-187Vitamin D Supplementation is Beneficial for Children with Autism Spectrum Disorder: A Meta-analysisDan Wang, Ai Chen, Lifang Zhou, Zhi Chen, Qing Jiang, Xiaomei Luo, Liyao Songpp. 203-213Lithium Stabilizes the Mood of Bipolar Patients by Depolarizing the Neuronal Membrane Via Quantum Tunneling through the Sodium ChannelsAbdallah Barjas Qaswalpp. 214-218The Neurochemical Effects of Prazosin Treatment on Fear Circuitry in a Rat Traumatic Stress ModelMehmet Zafer Gören, Hülya Cabadak, Banu Aydın, Gökçe Elif Sarıdoğan, Nazife Gökçe Acet, Sema Ketencipp. 219-230ZNF804A Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood DisordersLaura Mandelli, Prakash S Masand, Marco Calabrò, Marco Di Nicola, Roberto Colombo, Luigi Janiri, Tae-Youn Jun, Sheng Min Wang, Alessandro Serretti, Changsu Han, Chi-Un Pae, Soo-Jung Lee, Ashwin A Patkar, Concetta Crisafullipp. 231-240
원문 보기